STOCK TITAN

Octagon group discloses 6.4% Palisade Bio (PALI) stake in Schedule 13G

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Palisade Bio, Inc. received a new large shareholder disclosure from Octagon Capital Advisors LP, Octagon Investments Master Fund LP, and Ting Jia. The group reports beneficial ownership of 9,567,898 shares of Palisade Bio common stock, representing 6.4% of the outstanding class.

The ownership is held through Octagon Investments Master Fund, with Octagon acting as investment manager and Ting Jia as the control person of Octagon. The filing states the securities were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of Palisade Bio.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Octagon Capital Advisors LP
Signature:/s/ Ting Jia
Name/Title:Managing Member
Date:02/10/2026
Octagon Investments Master Fund LP
Signature:/s/ Ting Jia
Name/Title:Managing Member, Octagon Investments GP, LLC, its general partner
Date:02/10/2026
Ting Jia
Signature:/s/ Ting Jia
Name/Title:Ting Jia
Date:02/10/2026

FAQ

How many Palisade Bio (PALI) shares does Octagon report owning?

Octagon Capital Advisors, Octagon Investments Master Fund, and Ting Jia report beneficial ownership of 9,567,898 Palisade Bio common shares. These shares are held through Octagon Investments Master Fund, with Octagon as investment manager and reflect a significant institutional position in the company.

What percentage of Palisade Bio (PALI) is owned by the reporting group?

The reporting group states it beneficially owns 6.4% of Palisade Bio’s common stock. This percentage is calculated using 149,003,210 common shares outstanding as of November 5, 2025, as reported by Palisade Bio in a previously filed quarterly report.

Who are the reporting persons in this Palisade Bio (PALI) Schedule 13G?

The Schedule 13G is jointly filed by Octagon Capital Advisors LP, Octagon Investments Master Fund LP, and Ting Jia. Octagon manages the Master Fund, and Ting Jia is the managing member and control person of Octagon, giving each a deemed beneficial ownership interest.

Is Octagon’s stake in Palisade Bio (PALI) a passive investment?

The filing certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Palisade Bio. It also states they are not held in connection with any transaction aimed at influencing control.

Who has voting and dispositive power over the Palisade Bio (PALI) shares?

The reporting group discloses shared voting power and shared dispositive power over 9,567,898 shares, and no sole voting or dispositive power. This means decisions on voting and selling these shares are made jointly under their stated relationships.

On what date did Octagon’s Palisade Bio (PALI) ownership trigger this filing?

The Schedule 13G lists December 31, 2025 as the date of the event requiring the filing. That date reflects when their beneficial ownership position met the regulatory threshold that requires public disclosure on a Schedule 13G.
Palisade Bio Inc

NASDAQ:PALI

PALI Rankings

PALI Latest News

PALI Latest SEC Filings

PALI Stock Data

258.12M
136.49M
0.24%
5.92%
3.6%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CARLSBAD